Canada Markets closed

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
6.700.00 (0.00%)
At close: 01:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close6.70
Open6.70
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.70 - 6.70
52 Week Range6.03 - 11.25
Volume65
Avg. Volume2
Market Cap168.074M
Beta (5Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)-1.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases

    LYON, France, December 06, 2021--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced the formation of its Scientific Advisory Board (SAB) for rare metabolic diseases. The new SAB will initially focus on supporting Poxel's X-linked adrenoleukodystrophy (ALD) program.

  • Business Wire

    Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November

    LYON, France, November 03, 2021--POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in November 2021.

  • Business Wire

    Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021

    LYON, France, October 20, 2021--POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2021.